✦   ✦   ✦

breaking news

News, read through The Primal Race
← 全部评论 · all commentary

Ozempic:一种被药物化的“最优解表达”Ozempic: A Pharmacological 'Optimal Expression' of Submission

性别 结构层 · 文化层 · 元暴力 The New York Times ↗ 2026-07-08 § 链接
减肥药不是在治疗肥胖,而是在给结构性歧视提供廉价的生物学补丁。
Weight-loss drugs aren't treating obesity; they are providing cheap biological patches for structural discrimination.

Caroline Calloway 绑沙袋骗药的行为,在很多人看来是某种“病态”或“虚荣”,但从存在性战争的视角看,这其实是一个极其理性的博弈。当一个社会通过文化暴力将“瘦”定义为尊严、工作机会和社交地位的门槛时,身体就成了一张入场券。Calloway 意识到,试图在有生之年通过抗争来修正父权制的审美霸权是不可能的,那么在既定规则下,通过药物强行修改生物表型,就是她能找到的真.最优解表达——即便代价是胃肠道的痛苦。

NBER 的研究数据撕开了这个 scam 的遮羞布:GLP-1 药物让单身女性的结婚率提升 18%,让失业女性的就业率提升 13%。请注意,药物改变的不是这些女性的劳动能力或人格魅力,而是她们的 BMI。这意味着,市场在雇佣和选择伴侣时,依然在执行一套极其粗糙的“第一印象”筛选机制。这种 Obesity Penalty(肥胖惩罚)本质上是结构性暴力,它将女性的价值与一个数字挂钩,而 GLP-1 只是让弱势者在不改变结构的前提下,通过自我损耗来换取一点点生存空间的宽容。

这正是最阴险的地方:当“瘦”可以通过药物购买时,社会对肥胖者的宽容度不但不会增加,反而会进一步降低。因为“你可以通过打针变瘦”,那么不愿或不能打针的女性,将被贴上“缺乏自律”或“道德缺陷”的标签。GLP-1 将一个结构性压迫问题转化为了一个生物学管理问题。人们不再讨论为什么社会要歧视胖女人,而是在讨论如何更高效地把她们变成瘦女人。

这是一种典型的共谋。制药巨头通过垄断认知入口,将药物包装成“奇迹”;而个体在绝望中通过药物完成自我规训,以确保自己在男性中心叙事的评价体系中不至于太狼狈。我们以为在追求健康,实际上是在为那个把女性客体化的旧世界递交投名状。

Caroline Calloway’s act of wearing ankle weights to deceive a doctor is viewed by many as 'pathological' or 'vain.' However, through the lens of Existential War, this is a rational gamble. When a culture uses cultural violence to define 'thinness' as the threshold for dignity, employment, and social status, the body becomes an admission ticket. Calloway realized that attempting to dismantle the patriarchal aesthetic hegemony in her lifetime was futile. Thus, forcibly altering her phenotype via drugs became her optimal expression—even if the cost was gastrointestinal suffering.

The NBER data strips away the facade of this scam: GLP-1s increase marriage probability for single women by 18% and employment by 13%. Note that the drug doesn't improve their labor capacity or personality; it only changes their BMI. This proves that the market still operates on a crude 'first-impression' screening mechanism. This Obesity Penalty is a form of structural violence that ties a woman's value to a number. GLP-1s simply allow the disadvantaged to trade self-attrition for a sliver of systemic tolerance without challenging the structure itself.

This is the most insidious part: when thinness becomes purchasable, social tolerance for fatness doesn't increase—it decreases. The logic shifts to: 'Since you can just take a shot to get thin,' any woman who cannot or will not do so is labeled as 'lacking self-discipline' or 'morally deficient.' GLP-1s transform a structural oppression problem into a biological management problem. We stop questioning why society discriminates against fat women and start discussing how to efficiently turn them into thin ones.

It is a perfect state of complicity. Big Pharma monopolizes the cognitive entry by branding the drug as a 'miracle,' while individuals, in desperation, engage in self-discipline to avoid being too pathetic within the masculine-centric narrative. We believe we are pursuing health, but we are actually submitting a pledge of allegiance to an old world that continues to objectify women.